Retatrutide and Tirzepatide represent a major evolution in metabolic pharmacology. Both are synthetic peptide agonists designed to treat obesity and type 2 diabetes by targeting incretin biology, but they differ significantly in receptor profile, metabolic impact, and physiological consequences. Understanding their mechanistic differences is essential for evaluating their effects on fat loss, energy expenditure, glucose […]Read More
Before semaglutide, tirzepatide, and retatrutide took the world by storm, there was Liraglutide, the first GLP-1 receptor agonist to demonstrate that manipulating incretin hormones could dramatically improve weight loss, glucose control, and metabolic function. Marketed under the brand names Victoza and Saxenda, liraglutide paved the way for the next generation of GLP-based drugs that are […]Read More
GLP-1 receptor agonists, once known only as diabetes medications, have transformed into some of the most effective drugs for obesity and metabolic health. Compounds like Semaglutide, Tirzepatide, and the newer triple agonist Retatrutide have shown unmatched benefits in fat loss, insulin sensitivity, and cardiovascular protection. Emerging evidence now suggests that these drugs may also carry […]Read More
Tirzepatide is a promising new drug belonging to the GLP-1 and GIP Receptor Agonist classes of drugs that has recently been approved by the US Food and Drug Administration (FDA) for the treatment of type 2 diabetes. It appears as an alternative to Ozempic (Semaglutide), which has rapidly become a popular weight-loss medication among […]Read More
In order to achieve and maintain a lower bodyweight, be it for aesthetic or health-related reasons, people often try various methods, including the use of medications that, although initially designed to help with type-2 diabetes, also aid in weight loss. Two very important options in this class are Mounjaro (tirzepatide) and Ozempic (semaglutide). This article […]Read More
© 2026 Steroidify. All rights reserved. Privacy Policy. Contact Us.
